Sunday, June 25
6:45–7:45 am CT
Navigating the New Era of Molecularly-Defined Care in Alzheimer's Disease: Applying Nuclear Medicine to Quantify Neuropathology and Improve Diagnostic Accuracy in the Earliest Stages of the AD Continuum (CME-Certified Symposium)
- Co-Chair & Presenter: Gil Rabinovici, MD; Edward Fein & Pearl Landrith Distinguished Professor; Director, UCSF Alzheimer’s Disease Research Center Departments of Neurology, Radiology and Biomedical Imaging; University of California, San Francisco; San Francisco, California
- Co-Chair & Presenter: Ilya M. Nasrallah, MD, PhD; Department of Radiology; University of Pennsylvania; Philadelphia, Pennsylvania
Significant advances have been made in the development and validation of molecular imaging tools and quantitation techniques that may aid in the detection and diagnosis of Alzheimer’s disease (AD). Join PeerView for this educational symposium, where a panel of AD experts will illustrate how to integrate validated and emerging PET radiotracers and quantitative measures into clinical practice. Through a case-based discussion, this interactive symposium will offer learners an in-depth look at the complex diagnostic challenges associated with mild cognitive impairment and early AD dementia, and will provide practical guidance on effectively and appropriately incorporating amyloid PET, FDG PET, and tau PET imaging into patient care to facilitate timely and accurate AD diagnosis. Attendees will also learn about quantitation tools that can improve the diagnostic accuracy, sensitivity, and specificity of PET image interpretation.
For more information, please visit: PeerView.com/AD2023-Live
This CME activity is provided by PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Lilly.
6:45–7:45 am CT
Unleashing the Power of Total-Body PET/CT: Reflections on 5 Years of Progress
- Dr. Ramsey Badawi,Vice-Chair for Research, Department of Radiology, UC Davis
- Dr. Hongcheng Shi, Director, Department of Nuclear Medicine, Zhongshan Hospital of Fudan University
- Dr. Harshad Kulkarni, Chief Medical Advisor, BAMF Health
- Dr. Zhi Yang,Director, Department of Nuclear Medicine, Peking Cancer Hospital
Witness the Extraordinary Capabilities of uEXPLORER®: The World's First and Only 2 m Total-Body PET/CT Scanner. Join us for an enlightening session as we explore a captivating showcase of the latest breakthroughs in clinical and research domains.
11:15 am–12:15 pm CT
PSMA PET: Imaging Engineered
This presentation will discuss the most recent innovation in PSMA-PET imaging for prostate cancer.
11:15 am–12:15 pm CT
PSMA PET Imaging: Five Years of Experience from Research to Clinical Use
Andrei Iagaru, MD, Professor of Radiology - Nuclear Medicine and Chief, Division of Nuclear Medicine and Molecular Imaging atStanford University
PSMA PET changed the way that patients with prostate cancer are managed from initial treatment to biochemical recurrence. Here we will review data from the research use to clinical implementation, as well as new emerging uses and the introduction of artificial intelligence for scan interpretation and reporting.
11:15 am–12:15 pm CT
Utilizing Imaging to Identify Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) for Appropriate Diagnosis and Treatment
Saurabh Malhotra, MD, MPH, FACC, FASNC, Director of Advanced Cardiac Imaging and Amyloidosis Program, Associate Professor of Medicine, Cook County Health, Chicago, IL
Transthyretin amyloid cardiomyopathy (or ATTR-CM) is a serious underrecognized and underdiagnosed disease that frequently presents as heart failure. Join us to help raise awareness of the signs and symptoms of ATTR-CM, and the role of cardiac health professionals in suspecting, diagnosing, and confirming ATTR-CM. This presentation will introduce approaches to achieve a diagnosis—with a focus on nuclear scintigraphy and include a review of the clinical data for a treatment option for ATTR-CM.
6:30–7:30 pm CT
Timely Alzheimer's Disease Diagnosis for Clinical Management: The Integrated Role of PET Imaging
- Giuseppe Esposito, MD, Chief of Nuclear Medicine & PET/CT, Professor of Radiology, MedStar Georgetown University Hospital, Washington, DC, USA
- R Scott Turner, MD, PhD, Director, Memory Disorders Program, Professor, Dept of Neurology, Georgetown University Medical Center, Washington, DC, USA
Please join us as two clinical experts in the fields of Neurology and Nuclear Medicine discuss the role of PET imaging in the diagnosis and management of mild cognitive impairment (MCI) and dementia associated with Alzheimer’s disease (AD). The speakers will provide insights on topics including: the key features and imaging scenarios encountered in MCI and AD dementia, interpreting scans for amyloid deposition, comparing the various amyloid PET ligands, the role of amyloid PET imaging in AD diagnosis, optimizing the communication of imaging discussions with the multi-disciplinary team, and learnings from the original and ongoing Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) studies and New IDEAS studies. The session will highlight the perspective of a collaborative clinical team and how imaging can be incorporated into the management and decision-making of patients with suspected AD. This session, which will include dialogue between the experts and practical illustrative case studies, aims to provide information to healthcare professionals that may be helpful for improving the diagnosis and clinical management of AD.
6:30–7:30 pm CT
Investing Into the Future of Theranostics: Aligning Supply to the Clinical Needs
- Dr. Harshad Kulkarni, BAMF Health - Current and future utilization of Theranostics: A clinical perspective
- Neil Quigley, M.Sc. - Synergy between Lu-177 & Ac-225: A radiochemistry perspective
- Ram Mullur, M.Sc., MBA VP-Canadian National Laboratories - Commercial Availability of Ac-225: A Technology perspective
This session examines the current landscape and promising future of theranostics, from three distinct but equally important vantage points: The clinician, the radiochemist, and the manufacturer. Understanding the interdependency of these stakeholders will help ensure the value of this critical modality for patients now and well into the future.
6:30–8:30 pm CT
Sponsored by: SOFIE
FAP Ligands for Imaging and Therapy
Frederik L. Giesel, MD, MBA, University Hospital Düsseldorf
Andrew Scott, MBBS (Hons), MD, FRACP, FAHMS, FAICD, FAANMS
Olivia Newton-John Cancer Research Institute
Rodney Hicks, MBBS (Hons), MD, FRACP, FICIS, FAAHMS
Melbourne Theranostic Innovation Center
Current State of FAP Imaging
Ajit Goenka, MD, Mayo Clinic
Elcin Zan, MD, Cornell University
Ali Pirasteh, MD, UW Madison
Frank Bengel, MD, Medical School Hannover
Current State of FAP Therapeutics
Wolfgang P. Fendler, MD, Essen University Hospital
Mark Sellmyer, MD, PhD, University of Pennsylvania
Delphine Chen, MD, University of Washington
Clinical Development/Industry Updates
Sherly Mosessian, PhD, SOFIE
Jacqueline Mock, PhD, Philochem, Philogen
Amanda Walker, MD, POINT Biopharma
Xiaoyuan (Shawn) Chen, PhD, National University of Singapore
Panel Discussion – moderated by Frederik L. Giesel, MD, MBA
Tadashi Watabe, MD, PhD, FANMB, Osaka University
Vasko Kramer, PhD, Positronpharma SA
Haojun (Leo) Chen, MD, First Affiliated Hospital of Xiamen University
Jeremie Calais, MD, Msc, University of California, Los Angeles
FAP (fibroblast activation protein) as a diagnostic and therapeutic target for radiopharmaceuticals has seen many advances in recent years. This special session will bring together researchers and industry sponsors to discuss the latest progress in this space.
Flyers: SOFIE, Philogen/Philochem, and Yantai